| Literature DB >> 34268154 |
Luxwell Jokonya1,2, Aaron Musara1, Ignatius Esene3, Tariro Lavender Mduluza-Jokonya2, Rudo Makunike-Mutasa4, Sally Rothemeyer5, Kazadi Kaluile Ntenge Kalangu1, Takafira Mduluza6, Thajasvarie Naicker2.
Abstract
INTRODUCTION: Gliomas are tumors of the supporting cells of the central nervous system. They have great heterogeneity in their clinical and pathological features as well as prognosis. There is paucity of glioma epidemiology data in Zimbabwe. We carried out a study to determine the landscape, presentation, and characteristics of brain gliomas in Zimbabwe.Entities:
Keywords: Brain glioma; Zimbabwe; brain tumors; epidemiology of brain glioma
Year: 2021 PMID: 34268154 PMCID: PMC8244682 DOI: 10.4103/ajns.AJNS_404_20
Source DB: PubMed Journal: Asian J Neurosurg
Figure 1Trial profile
Participants demographics
| Demographic variable | Frequency |
|---|---|
| Age (years), mean (SD) | 41.8 (22.4) |
| Sex | |
| Male | 47% (22) |
| Female | 53% (25) |
| Race | |
| Black | 85% (40) |
| Caucasian | 15% (7) |
| Occupation | |
| Minor/student | 26% (12) |
| Unemployed | 23% (11) |
| Employed | 51% (24) |
| Geographic location (province) | |
| Harare | 57% (27) |
| Bulawayo | 15% (7) |
| Midlands | 9% (4) |
| Mashonaland west | 6% (3) |
| Matabeleland south | 4.3% (2) |
| Mashonaland central | 2% (1) |
| Masvingo | 2% (1) |
| Matabeleland north | 2% (1) |
| Manicaland | 2% (1) |
| Residence | |
| Urban | 85% (40) |
| Rural | 15% (7) |
SD - Standard deviation
Timeline for referral to neurosurgeons
| 0-3 months | 4-6 months | 7-9 months | 10-12 months | Total | |
|---|---|---|---|---|---|
| Total | 74% (32) | 18.6% (8) | 4.7% (2) | 2.3% (1) | 100% (43) |
Predictive clinical indicators for high-grade glioma regression analyses for the effect of gender, age, performance status, and duration of different presenting symptoms
| Features | Adjusted OR | 95% CI |
|---|---|---|
| Gender | ||
| Female | 1 (reference) | 1 (reference) |
| Male | 1.27 | 0.40-4.02 |
| Age (years) | ||
| <10 | 1 (reference) | 1 (reference) |
| 10-20 | 0.13* | 0.02-0.92 |
| 20-40 | 0.41 | 0.09-1.82 |
| 40-60 | 4.15* | 1.15-14.92 |
| >60 | 13.20* | 1.51-115.35 |
| Performance status at presentation (%) | ||
| 0 (10) | 1 (reference) | 1 (reference) |
| 1 (20-40) | 1.11 | 0.20-6.15 |
| 2 (50-70) | 1.27 | 0.40-4.02 |
| 3 (80-100) | 0.73 | 0.22-2.35 |
| Headache (months) | ||
| None | 1 (reference) | 1 (reference) |
| <3 | 3.80* | 1.09-13.18 |
| 3-6 | 4.00 | 0.75-21.35 |
| 7-9 | 0.36 | 0.01-9.37 |
| >10 | 0.11* | 0.012-0.99 |
| Seizures (months) | ||
| None | 1 (reference) | 1 (reference) |
| <3 | 0.14 | 0.01-1.20 |
| 3-6 | 2.62 | 0.25-27.18 |
| 7-9 | 0.88 | 0.50-14.80 |
| >10 | 0.10 | 0.01-2.09 |
| Memory loss (months) | ||
| None | 1 (reference) | 1 (reference) |
| <3 | 5.08* | 1.16-15.39 |
| 3-6 | 2.86 | 0.28-29.75 |
| 7-9 | 0.36 | 0.01-9.37 |
| >10 | 0.73 | 0.11-4.84 |
| Focal deficit (months) | ||
| None | 1 (reference) | 1 (reference) |
| <3 | 0.40 | 0.07-2.31 |
| 3-6 | 0.84 | 0.05-14.26 |
| 7-9 | 2.76 | 0.76-10.13 |
| >10 | 3.9* | 1.13-13.45 |
| Cognitive change (months) | ||
| None | 1 (reference) | 1 (reference) |
| <3 | 6.2 | 0.28-13.69 |
| 3-6 | 0.36 | 0.01-9.37 |
| 7-9 | 2.40 | 0.20-28.45 |
| >10 | 1.54 | 0.36-6.66 |
*Statistical significance at 5% (P<0.05). CI - Confidence interval; OR - Odds ratio
Figure 2Tumor distribution in the brain
Presentation
| Variable | Frequency % ( |
|---|---|
| Headache | 89% (42) |
| Seizures | 32% (15) |
| Memory loss | 43% (20) |
| Weakness | 64% (30) |
| Visual loss | 38% (18) |
| Language deficit | 9 % (4) |
| Cognition | 19% (9) |
| Personality | 17% (8) |
| Change in consciousness | 43% (20) |
| Nausea and vomiting | 51% (24) |